# XOMA Royalty Corp (XOMAP) — merger/definitive [pending] Source: sec.gov · situation sit_7e5fa01740e77e5a450d · public 4223193733635309968 · retrieved 2026-08-21T14:15:14.195Z ## Overview We also acquire milestone and royalty revenue streams on late-stage clinical assets and commercial assets that are designed to address unmet markets or have a therapeutic advantage over other treatment options and have long duration of market exclusivity. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240.14a-12 XOMA ROYALTY CORPORATION (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): ☐ No fee required ☒ Fee paid previously with preliminary materials ☐ Fee com... ## Key dates - Announced 2026-05-26 ## Timeline - 2026-05-26 · 425 (0001193125-26-238267): 425 - XOMA Royalty Corp — *We also acquire milestone and royalty revenue streams on late-stage clinical assets and commercial assets that are designed to address unmet markets or have a therapeutic advantage over other treatment options and have long duration of market exclusivity.* PRELIMINARY-SUBJECT TO COMPLETION, DATED MAY 22, 2026 MERGER AND REORGANIZATION PROPOSALS-YOUR VOTE IS VERY IMPORTANT Dear Stockholders: On April 27, 2026, XOMA Royalty Corporation, a Nevada corporation (the "Company" or "XOMA Royalty"), Ligand Pharmaceuticals Incorporated, a Delaware corporation ("Parent"), and Flex Merger Sub, Inc., a Nevada corporation and wholly owned subsidiary of Parent ("Merger Sub"), entered into an Agreement and Plan of Merger, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026, by and among XOMA Royalty, Parent, Merger Sub and XOMA Royalty Holdings Corporation, a Nevada corporation and wholly owned subsidiary of XOMA Royalty ("HoldCo"), as it may be amended from time to time (as amended, the "Merger Agreement"). https://www.sec.gov/Archives/edgar/data/791908/0001193125-26-238267.txt - 2026-06-10 · DEFM14A (0001193125-26-266069): DEFM14A - XOMA Royalty Corp — *We also acquire milestone and royalty revenue streams on late-stage clinical assets and commercial assets that are designed to address unmet markets or have a therapeutic advantage over other treatment options and have long duration of market exclusivity.* 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240.14a-12 XOMA ROYALTY CORPORATION (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): ☐ No fee required ☒ Fee paid previously with preliminary materials ☐ Fee com... https://www.sec.gov/Archives/edgar/data/791908/0001193125-26-266069.txt ## Citations - 0001193125-26-238267 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526238267 - 0001193125-26-266069 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526266069